Biotechnology

New data suggests Phanes Therapeutics' bispecific antibody may overcome major side effects of CD47 inhibitors while showing promise in tough GI cancers.

Cingulate Inc. faces a critical FDA decision for its novel ADHD drug, but manufacturing queries and a tight cash runway create a high-stakes countdown.

Artelo Biosciences is testing a novel cannabinoid drug for glaucoma, aiming to protect vision in a way current treatments can't—all without diluting shares.

With veteran leader Brian McKelligon at the helm, Infinity Bio aims to commercialize its powerful MIPSA platform and redefine precision medicine.

A landmark deal between Australia's VVMF and UK's OXB aims to create a new cell and gene therapy manufacturing hub for the booming Asia-Pacific market.

A new partnership will leverage genetically engineered mice to create novel antibody drugs, potentially unlocking treatments for cancer and brain diseases.

With a massive $68.7M seed round and novel T-cell engager tech, Shanghai's Excalipoint is pioneering a new model for rapid drug development.

ACTO's new AI suite automates workflows, promising to boost efficiency and compliance for pharma and medtech field professionals while keeping humans in control.

InflaRx announces a late-breaking presentation on its Phase 3 trial for vilobelimab, offering potential new hope for pyoderma gangrenosum patients.

With a new CEO and Chair, IsomAb is advancing a disease-modifying drug for 9 million angina patients, eyeing a major Series A fundraise.

A new partnership seeks to conquer C. difficile, a deadly hospital infection that has stumped pharma giants, by advancing a novel dual-action vaccine.

A new collaboration will use innovative protein binders to fight animal disease, bolstering global food security and public health under the One Health framework.

New preclinical data reveals a novel gene therapy that not only kills tumor cells but also boosts immunity, offering hope against drug-resistant lung cancer.

A novel drug mimicking exercise aims to solve a major problem with today's weight-loss meds: muscle loss. Atrogi's ATR-258 has entered a key human trial.

Indian jeweler Aukera unveils its Extra Brilliant™ Solitaire, using light science and 2.5x more facets to challenge diamond industry traditions.

SAB Biotherapeutics' public offering fuels late-stage trials for its promising T1D drug, SAB-142, aiming to change the treatment landscape.

DNA Script's global expansion brings benchtop DNA printers to new markets, promising to accelerate research and decentralize biotech supply chains.

The deal, part of a broader consolidation strategy by parent The Lockwood Group, aims to meet rising pharma demand for advanced data and patient services.

With late-breaking hypertension data and an AI-driven platform, Kardigan is set to showcase a new, personalized approach to cardiovascular medicine.

A new strategic partnership aims to unite California's life science hubs, creating a streamlined path to capital for medtech and biotech startups.